Role of endothelin-1 in the skin fibrosis of systemic sclerosis

European Cytokine Network

Volumn 26, Issue 1, 2015, Pages 10-14

  Jing, J ^a   Dou, T T ^a   Yang, J Q ^a   Chen, X B ^a   Cao, H L ^a   Min, M ^a   Cai, S Q ^a   Zheng, M ^a   Man, X Y ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Akt; Endothelin 1; Fibroblast; Smad; Systemic sclerosis

Indexed keywords

COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; ENDOTHELIN 1; FIBRONECTIN; PROTEIN KINASE B; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; CTGF PROTEIN, HUMAN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT PROTEIN; SERPINE1 PROTEIN, HUMAN; SMAD2 PROTEIN, HUMAN; SMAD3 PROTEIN, HUMAN;

ADULT; ARTICLE; BIOPSY; CHEMOLUMINESCENCE; CLINICAL ARTICLE; FEMALE; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; UPREGULATION; WESTERN BLOTTING; BIOSYNTHESIS; CASE CONTROL STUDY; DRUG EFFECTS; FIBROBLAST; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; PRIMARY CELL CULTURE; SECRETION (PROCESS); SKIN;

ADULT; CASE-CONTROL STUDIES; COLLAGEN TYPE I; CONNECTIVE TISSUE GROWTH FACTOR; ENDOTHELIN-1; FEMALE; FIBROBLASTS; FIBRONECTINS; FIBROSIS; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; PHOSPHORYLATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRIMARY CELL CULTURE; PROTO-ONCOGENE PROTEINS C-AKT; RECOMBINANT PROTEINS; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SKIN; SMAD2 PROTEIN; SMAD3 PROTEIN;

EID: 84932165731     PISSN: 11485493     EISSN: 19524005     Source Type: Journal    
DOI: 10.1684/ecn.2015.0360     Document Type: Article

References (27)

1. Aghaei M, Gharibdost F, Zayeni H, et al. Endothelin-1 in systemic sclerosis. Indian Dermatol Online J 2012; 3: 14-6.
2. Shiwen X, Leask A, Abraham DJ, Fonseca C. Endothelin receptor selectivity: evidence from in vitro and pre-clinical models of scleroderma. Eur J Clin Invest 2009; 39(Suppl 2): 19-26.
3. Shi-Wen X, Denton CP, Dashwood MR, et al. Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 2001; 116: 417-25.
4. Goldie RG, Knott PG, Carr MJ, Hay DW, Henry PJ. The endothelins in the pulmonary system. Pulm Pharmacol 1996; 9: 69-93.
5. Weng CM, Yu CC, Kuo ML, Chen BC, Lin CH. Endothelin-1 induces connective tissue growth factor expression in human lung fibroblasts by ETAR-dependent JNK/AP-1 pathway. Biochem Pharmacol 2014; 88: 402-11.
6. Davenport AP, Maguire JJ. Endothelin. Handb Exp Pharmacol 2006: 295-329.
7. Leask A. Targeting the TGFbeta, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma. Cell Signal 2008; 20: 1409-14.
8. Morris E, Chrobak I, Bujor A, et al. Endoglin promotes TGFbeta/Smad1 signaling in scleroderma fibroblasts. J Cell Physiol 2011; 226: 3340-8.
9. Yamane K, Kashiwagi H, Suzuki N, et al. Elevated plasma levels of endothelin-1 in systemic sclerosis. Arthritis Rheum 1991; 34: 243-4.
10. Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum 1991; 34: 978-83.
11. Kim HS, Park MK, Kim HY, Park SH. Capillary dimension measured by computer-based digitalized image correlated with plasma endothelin-1 levels in patients with systemic sclerosis. Clin Rheumatol 2010; 29: 247-54.
12. Sulli A, Soldano S, Pizzorni C, et al. Raynaud’s phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis. J Rheumatol 2009; 36: 1235-9.
13. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23:581-90.
14. Lonzetti LS, Joyal F, Raynauld JP, et al. Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. Arthritis Rheum 2001; 44: 735-6.
15. Man XY, Finnson KW, Baron M, Philip A. CD109, a TGF-beta coreceptor, attenuates extracellular matrix production in scleroderma skin fibroblasts. Arthritis Res Ther 2012; 14: R144.
16. Li W, Man XY, Li CM, et al. VEGF induces proliferation of human hair follicle dermal papilla cells through VEGFR-2-mediated activation of ERK. Exp Cell Res 2012; 318: 1633-40.
17. Zhou J, Man XY, Li W, Chen JQ, Cai SQ, Zheng M. Regulation of integrin alpha5 and beta4 in normal and scleroderma epidermal keratinocytes. Br J Dermatol 2012; 166: 1369-70.
18. Jing J, Wu XJ, Li YL, Cai SQ, Zheng M, Lu ZF. Expression of decorin throughout the murine hair follicle cycle: hair cycle dependence and anagen phase prolongation. Exp Dermatol 2014; 23: 486-91.
19. Trojanowska M. Noncanonical transforming growth factor beta signaling in scleroderma fibrosis. Curr Opin Rheumatol 2009; 21: 623-9.
20. Ghosh AK, Vaughan DE. PAI-1 in tissue fibrosis. J Cell Physiol 2012; 227: 493-507.
21. Li R, Wang Y, Liu Y, et al. Curcumin inhibits transforming growth factor-beta1-induced EMT via PPARgamma pathway, not Smad pathway in renal tubular epithelial cells. PLoS One 2013; 8: e58848.
22. Marut W, Jamier V, Kavian N, et al. The natural organosulfur compound dipropyltetrasulfide prevents HOCl-induced systemic sclerosis in the mouse. Arthritis Res Ther 2013; 15: R167.
23. Rodriguez-Pascual F, Busnadiego O, Gonzalez-Santamaria J. The profibrotic role of endothelin-1: Is the door still open for the treatment of fibrotic diseases? Life Sci 2014; 118: 156-64.
24. Jun JB, Kuechle M, Min J, et al. Scleroderma fibroblasts demonstrate enhanced activation of Akt (protein kinase B) in situ. J Invest Dermatol 2005; 124: 298-303.
25. Shi-Wen X, Chen Y, Denton CP, et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004; 15: 2707-19.
26. Furuya Y, Kuwana M. Effect of Bosentan on systemic sclerosisassociated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study. J Rheumatol 2011; 38: 2186-92.
27. Giordano N, Puccetti L, Papakostas P, et al. Bosentan treatment for Raynauds phenomenon and skin fibrosis in patients with Systemic Sclerosis and pulmonary arterial hypertension: an open-label, observational, retrospective study. Int J Immunopathol Pharmacol 2010; 23: 1185-94.